274 related articles for article (PubMed ID: 18197727)
1. Looking to the future for erectile dysfunction therapies.
Hatzimouratidis K; Hatzichristou DG
Drugs; 2008; 68(2):231-50. PubMed ID: 18197727
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase type 5 inhibitors: unmet needs.
Hatzimouratidis K; Hatzichristou DG
Curr Pharm Des; 2009; 15(30):3476-85. PubMed ID: 19860693
[TBL] [Abstract][Full Text] [Related]
3. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
Hatzimouratidis K; Hatzichristou DG
Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698
[TBL] [Abstract][Full Text] [Related]
4. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.
Bruzziches R; Francomano D; Gareri P; Lenzi A; Aversa A
Expert Opin Pharmacother; 2013 Jul; 14(10):1333-44. PubMed ID: 23675780
[TBL] [Abstract][Full Text] [Related]
5. Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties.
Kedia GT; Uckert S; Assadi-Pour F; Kuczyk MA; Albrecht K
Ther Adv Urol; 2013 Feb; 5(1):35-41. PubMed ID: 23372609
[TBL] [Abstract][Full Text] [Related]
6. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
Limin M; Johnsen N; Hellstrom WJ
Expert Opin Investig Drugs; 2010 Nov; 19(11):1427-37. PubMed ID: 20939743
[TBL] [Abstract][Full Text] [Related]
7. Future prospects in the treatment of erectile dysfunction: focus on avanafil.
Alwaal A; Al-Mannie R; Carrier S
Drug Des Devel Ther; 2011; 5():435-43. PubMed ID: 22087063
[TBL] [Abstract][Full Text] [Related]
8. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
9. [New treatment options for erectile dysfunction. Pharmacologic and nonpharmacologic options].
Sperling H; Lümmen G; Schneider T; Rübben H
Herz; 2003 Jun; 28(4):314-24. PubMed ID: 12825147
[TBL] [Abstract][Full Text] [Related]
10. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
Wright PJ
Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
[TBL] [Abstract][Full Text] [Related]
11. PDE5 inhibitors: considerations for preference and long-term adherence.
Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
[TBL] [Abstract][Full Text] [Related]
12. An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction.
Palit V; Eardley I
Nat Rev Urol; 2010 Nov; 7(11):603-9. PubMed ID: 21068761
[TBL] [Abstract][Full Text] [Related]
13. Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior.
Hedelin H; Ströberg P
Drugs; 2005; 65(16):2245-51. PubMed ID: 16266193
[TBL] [Abstract][Full Text] [Related]
14. [Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].
Porst H
Urologe A; 2004 Jul; 43(7):820-8. PubMed ID: 15197447
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
Martínez-Salamanca JI; Carballido J; Eardley I; Giuliano F; Gratzke C; Rosen R; Salonia A; Stief C
Eur Urol; 2011 Sep; 60(3):527-35. PubMed ID: 21684677
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
[TBL] [Abstract][Full Text] [Related]
17. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
18. The management of erectile dysfunction: innovations and future perspectives.
Leonardi R; Alemanni M
Arch Ital Urol Androl; 2011 Mar; 83(1):60-2. PubMed ID: 21585174
[TBL] [Abstract][Full Text] [Related]
19. Treatment of erectile dysfunction.
Dinsmore W
Int J STD AIDS; 2004 Apr; 15(4):215-21. PubMed ID: 15075013
[TBL] [Abstract][Full Text] [Related]
20. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
